RC
BRNS

Rangeley Capital’s Barinthus Biotherapeutics BRNS Stock Holding History

Rangeley Capital’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$90.7K Buy
159,465
+75,024
+89% +$49.4K 0.09% 120
2025
Q4 		$59.1K Buy
+84,441
New +$84.3K 0.05% 112

Other funds holding BRNS

MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
GP
GLR Partners Columbia, Maryland $215M AUM
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Rangeley Capital's BRNS Position: Q1 2026 in Review

Rangeley Capital increased its Barinthus Biotherapeutics (BRNS) stake by 89% in Q1 2026, buying an estimated $49.4K and bringing the position to 159,465 shares worth $90.7K. The position accounts for 0.09% of the portfolio, ranked #120.

Rangeley Capital first reported a position in BRNS in Q4 2025 and has held it in 2 quarters since. 14 funds tracked by Wall St. Rank hold BRNS as of Q1 2026.

  • Rangeley Capital held 159,465 shares of Barinthus Biotherapeutics worth $90.7K as of Q1 2026.
  • Rangeley Capital bought 75,024 Barinthus Biotherapeutics shares in Q1 2026, an estimated $49.4K.
  • Barinthus Biotherapeutics made up 0.09% of Rangeley Capital's portfolio in Q1 2026, its #120 holding.
  • Rangeley Capital first reported a position in Barinthus Biotherapeutics in Q4 2025 and has held it in 2 quarters since.
  • 14 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.